The Clear DCB Choice

Every Patient Deserves Stellarex

Learn More +

Top-tier outcomes with the lowest therapeutic drug dose in all patients—common to complex

Choose Efficacy

Stellarex exhibits consistent two-year patency across trials, even in the most complex PAD cases. Stellarex is the only DCB reported to have durable patency at 2 years in severely calcified lesions.

The Stellarex Difference

Stellarex’s unique coating composition, EnduraCoatTechnology, combines amorphous and small-to-large crystalline paclitaxel with polyethylene glycol (PEG) excipient. The result is efficient drug transfer, effective tissue residency, high coating durability and minimal particulate loss.

about the coating +

Help inform medicare CY2019 DCB Reimbursement

Learn More +

Choose Safety

Particulate loss is associated with an increased risk of downstream embolization. In bench tests, Stellarex demonstrated 79% less particulate loss than In.Pact.9

compare particulate +
Stellarex DCB Ballon

See more Stellarex clinical evidence

download brochure +